## Review setup
- **Input scope** Full manuscript text (Summary, Introduction, Methods, Usage guide and use cases, Future plans, Supplementary Material notice, Author contributions, Conflict of interests, Funding, Data availability)
- **Assessment boundary** Scientific content, methodological soundness, claims supported by the provided text, and suitability of the described resource for the stated purpose. No assessment of code functionality, web platform performance, or supplementary materials beyond what is described.
- **Shared manuscript claim summary** The authors present GRNContext, an interactive web platform for visualizing and exploring gene regulatory networks (GRNs) contextualized across 33 cancer types from TCGA. The platform integrates the TFLink human reference GRN with TCGA transcriptomic data, using Random Forest regression and Spearman correlation combined into a consensus score to prioritize transcription factors (TFs) for each target gene. Two case studies (PTTG1 in LIHC, RAB31 in OV) are presented to illustrate the platform's utility.
- **Visible evidence base** Full text of the manuscript, including methods description, two case study narratives, and quantitative claims about network size and conservation statistics (e.g., 835,367 edges, 68.45% cancer-specific, 0.13% conserved in ≥24 cancers).
- **Missing materials affecting confidence** Supplementary Materials (referenced but not provided), the actual web platform (not assessable from text), source code and data availability link (not inspected), detailed validation metrics for the consensus score, and any benchmarking against existing tools.

## Reviewer
- **Overall assessment** The manuscript describes a potentially useful web resource for cancer researchers interested in context-specific gene regulation. The core idea, contextualizing GRNs across TCGA cancer types with an accessible interface, addresses a real gap. However, the methodological description is thin in several critical areas, and the validation presented is anecdotal rather than systematic. The claims about the platform's utility and the biological significance of the case studies are not fully established from the provided evidence. The manuscript would benefit from clearer benchmarking, more rigorous validation of the consensus score, and a more complete description of the filtering and selection procedures.
- **Who would be interested in the results, and why** Experimental cancer biologists and translational researchers who lack advanced bioinformatics skills but need to generate hypotheses about TF-target relationships in specific tumor types. Computational biologists working on GRN inference may also find the resource useful as a reference or comparison point. The platform's accessibility and cross-cancer comparison features are likely to appeal to a broad audience in cancer genomics.
- **Major strengths**
  1. Addresses a clear and important gap: reference GRNs do not specify context-specific activity, and existing context-specific resources are not easily accessible to experimental biologists.
  2. The web platform design, with interactive visualization and cross-cancer comparison, is well conceived and likely to be genuinely useful.
  3. The use of complementary methods (RF regression and Spearman correlation) combined into a consensus score is a reasonable approach to prioritize regulators.
  4. The two case studies, particularly PTTG1, provide some face validity by recovering well-established regulators.
- **Major Concerns**
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Methodological soundness
  - **Claim pointer** "We developed a computational pipeline to identify which TFs regulate each gene in a cancer-specific manner... This approach combines Random Forest (RF) regression with Spearman's correlation analysis."
  - **Evidence pointer** Section 2.3, "Regulatory inference"
  - **Concern** The description of the consensus score calculation is incomplete. The authors state that Z-Score normalization and min-max scaling are applied to both RF importance scores and Spearman correlation values before combining, but the exact formula for the consensus score is not provided. It is unclear how the two metrics are weighted, whether the Spearman correlation is used as absolute value or signed, and how negative correlations (repression) are handled in the final score. Additionally, the RF model details are missing: number of trees, hyperparameters, train/test splits, and how overfitting was avoided.
  - **Why it matters** The consensus score is the central methodological contribution. Without a precise description, the results cannot be reproduced or independently evaluated. The handling of negative correlations is particularly important because the authors claim to distinguish activators from repressors, but the method for this distinction is not described.
  - **Resolution test** Provide the exact formula for the consensus score, including how Z-Score normalization and min-max scaling are applied, how the two metrics are combined, and how the sign of the Spearman correlation is treated. Describe RF hyperparameters and any cross-validation or performance metrics.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Validation and benchmarking
  - **Claim pointer** "The platform's ability to successfully retrieve and prioritize these well-established regulators validates its efficacy in identifying biologically relevant gene regulatory relationships."
  - **Evidence pointer** Section 3.1, "Case 1: PTTG1 in liver hepatocellular cancer (TCGA-LIHC)"
  - **Concern** The validation is based on a single anecdotal case (PTTG1) where known regulators were recovered. This is not a systematic validation. There is no comparison against existing tools (e.g., GRAND, ARACNe) or against random expectation. The authors do not report any quantitative performance metrics such as precision, recall, or area under the ROC curve for recovering known TF-target interactions across multiple genes or cancer types.
  - **Why it matters** A web resource of this type must demonstrate that its predictions are reliable. A single positive example is insufficient to establish efficacy, especially given the large number of edges (835,367) and the potential for false positives. Without benchmarking, users cannot assess the trustworthiness of the platform's output.
  - **Resolution test** Provide a systematic validation, e.g., using a gold standard set of TF-target interactions (such as ChIP-seq data) to compute precision and recall for the consensus score across multiple cancer types. Compare performance against at least one existing GRN inference tool.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** No
  - **Axis** Data and preprocessing transparency
  - **Claim pointer** "All available bulk RNA-Seq raw transcriptomic count matrices were downloaded from TCGA using the TCGA biolinks package (9927 samples spanning 33 different cancer types) and normalized using the Trimmed Mean of M-values (TMM) method implemented in edgeR."
  - **Evidence pointer** Section 2.1, "Transcriptomic data"
  - **Concern** The data processing description is minimal. The authors do not specify which TCGA data version or release was used, how gene-level counts were summarized (e.g., from which annotation), whether protein-coding genes only were retained, or how the TMM normalization was applied (e.g., per cancer type or across all samples). The exclusion threshold (median normalized expression below 10) is stated but its rationale is not given.
  - **Why it matters** Reproducibility requires precise data provenance. Different TCGA releases and processing pipelines can yield different results. The choice of threshold and gene filtering can materially affect the inferred networks.
  - **Resolution test** Specify the TCGA data version, gene annotation, and exact normalization and filtering steps. Provide a detailed data processing pipeline, ideally as a reproducible script or workflow.
  - **Concern ID** R1-M4
  - **Severity** Major
  - **Blocking** No
  - **Axis** Biological interpretation and claim support
  - **Claim pointer** "This cross-contextual evidence provides a strong mechanistic hypothesis generated by GRNContext, suggesting that the RUNX1-RAB31 regulatory axis may be conserved and functionally relevant in ovarian cancer, making further experimental validation necessary."
  - **Evidence pointer** Section 3.2, "Case 2: RAB31 in ovarian cancer (TCGA-OV)"
  - **Concern** The RAB31 case is presented as a hypothesis-generating example, which is appropriate, but the language "strong mechanistic hypothesis" overstates the evidence. The only support is a TF-target interaction observed in a different tissue (megakaryocytes) and the platform's prediction. No functional data, pathway context, or additional evidence from ovarian cancer is provided. The claim of "conserved and functionally relevant" is speculative.
  - **Why it matters** Overstating the strength of predictions can mislead users, particularly experimental biologists who may act on these hypotheses. The manuscript should clearly distinguish between validated findings and computational predictions.
  - **Resolution test** Soften the language to reflect the hypothesis-generating nature of the prediction. Provide additional supporting evidence, such as expression correlation in ovarian cancer, survival analysis, or literature on RUNX1 in ovarian cancer, if available.
- **Minor Comments**
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Clarity and completeness
  - **Affected element** Figure 1
  - **Evidence pointer** Section 1, "Introduction" (Figure 1 referenced)
  - **Issue** Figure 1 is referenced but not described in the text. The reader cannot understand what the figure shows without seeing it, and the text does not explain the workflow depicted.
  - **Required correction** Add a figure legend and a brief description in the text explaining the steps shown in Figure 1.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Reproducibility
  - **Affected element** Data availability
  - **Evidence pointer** "Data availability" section
  - **Issue** The data availability statement provides a Zenodo link for source code and supplementary materials, but it is not stated whether the full processed data (e.g., all inferred networks for all 33 cancer types) are included or only the code.
  - **Required correction** Clarify what exactly is available at the Zenodo link, including whether all processed network files are included.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Technical accuracy
  - **Affected element** Section 2.3, "Regulatory inference"
  - **Evidence pointer** Section 2.3
  - **Issue** The authors state that the elbow method "identifies the optimal number of regulators per gene," but the elbow method is a heuristic and does not guarantee an optimal solution. The description should acknowledge this limitation.
  - **Required correction** Rephrase to "identifies a data-driven cutoff" or similar, and briefly note the heuristic nature of the method.
  - **Concern ID** R1-m4
  - **Severity** Minor
  - **Axis** Presentation
  - **Affected element** Section 3, "Usage guide and use cases"
  - **Evidence pointer** Section 3
  - **Issue** The usage guide is written as instructions to the user, which is appropriate, but it is not clear whether the described features (e.g., "conservation popup," "right-click regulator nodes") are all currently implemented or planned.
  - **Required correction** Clarify which features are currently available in the live platform versus planned for future releases.
- **Technical failings that need to be addressed before the case is established**
  - R1-M1 (consensus score formula and RF details)
  - R1-M2 (systematic validation and benchmarking)
  - R1-M3 (data provenance and preprocessing details)

## Risk / unsupported claims
- The claim that the platform "validates its efficacy" based on a single case study (PTTTG1) is not supported by the provided evidence.
- The claim of a "strong mechanistic hypothesis" for RUNX1-RAB11 in ovarian cancer is overstated relative to the evidence presented.
- The global conservation statistics (835,367 edges, 68.45% unique, 0.13% conserved in ≥24 cancers) are presented without details on how these numbers were computed, making them difficult to evaluate.
- The statement that the consensus score "provides a unified measure of regulatory influence" is not fully supported without a precise definition of the score.
- The claim that the platform "supports mechanistic investigations, hypothesis generation, and translational research" is plausible but not demonstrated with concrete examples beyond the two case studies.

## Assessment against Nature-style criteria
- **Originality** Moderate. The idea of contextualizing GRNs across cancer types with an accessible web interface is not entirely novel, as tools like GRAND and ARACNe exist, but the specific combination of TFLink reference, consensus scoring, and user-friendly visualization may offer a new angle. The methodological novelty is limited, as the underlying statistical and machine learning approaches are well established.
- **Scientific importance** Moderate. The resource could be valuable for hypothesis generation in cancer biology, but the manuscript does not demonstrate a clear advance in understanding gene regulation. The importance is more in the tool's utility than in new biological insights.
- **Interdisciplinary readership** Moderate. The platform is designed for experimental biologists, which broadens its appeal, but the manuscript's technical depth may limit accessibility for non-specialists. The case studies help, but the methods section is dense.
- **Technical soundness** Currently not established. The consensus score is not fully described, validation is anecdotal, and data processing details are incomplete. These issues must be resolved before the technical approach can be assessed.
- **Readability for nonspecialists** Good in the introduction and usage guide, but the methods section assumes familiarity with RF regression, Z-Score normalization, and elbow methods. The case studies are clearly written and help illustrate the platform's use.

## Recommendation posture
Currently not established from the provided evidence. The manuscript describes a potentially useful resource, but the methodological description is incomplete, and the validation is insufficient to support the claims made. The authors should address the major concerns, particularly the consensus score formula, systematic benchmarking, and data provenance, before the case for the platform's utility is convincing. If these issues are resolved, the manuscript could be suitable for publication in a specialized bioinformatics or cancer genomics journal, though the scope and impact may be more limited than what Nature-style venues typically seek.